PEG ilodecakin - ARMO Biosciences

Drug Profile

PEG ilodecakin - ARMO Biosciences

Alternative Names: AM 0010; PEG-ilodecakin; PEG-rHuIL-10; Pegilodecakin; PEGylated Human IL-10; PEGylated Interleukin-10; PEGylated recombinant human Interleukin-10

Latest Information Update: 12 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Developer ARMO Biosciences
  • Class Anti-inflammatories; Antineoplastics; Immunotherapies; Interleukins; Polyethylene glycols
  • Mechanism of Action Interleukin-10 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase II Non-small cell lung cancer
  • Phase I Breast cancer; Colorectal cancer; Malignant melanoma; Ovarian cancer; Prostate cancer; Renal cell carcinoma
  • Preclinical Fibrosis; Hypercholesterolaemia; Inflammatory bowel diseases

Most Recent Events

  • 22 Feb 2018 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Recurrent) in USA (SC) (NCT03382899)
  • 04 Jan 2018 ARMO BioSciences plans the phase II Cypress 1 trial of AM 0010 in combination with pembrolizumab for Non small cell lung cancer (Combination therapy, Metastatic disease, Late-stage disease) in January 2018 (NCT03382899)
  • 25 Dec 2017 ARMO BioSciences plans a phase II trial for Non Small Cell Lung Cancer (Late-stage disease) in June 2018 , (NCT03382912)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top